Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of GH Research in a report released on ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against ...

Cantor Fitzgerald assumed coverage on shares of GH Research (NASDAQ:GHRS – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The firm issued an ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

GH Research (GHRS) announced the commencement of an underwritten public offering of $150M of ordinary shares. All of the ordinary shares are to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

周四 - Cantor Fitzgerald对GH Research PLC (NASDAQ: GHRS )给予"增持"评级，目标价设定为14.00美元。这一新的评级基于GHRS的GH001（一种吸入式5-MeO-DMT疗法）有望成为难治性抑郁症（TRD）标准疗法的潜力。Cantor ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the primary goal in a mid-stage study of its investigational, inhalable ...